Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Indivior PLC Board/Management Information 2018

Nov 16, 2018

4923_dirs_2018-11-16_17233ea4-2a23-4a53-ac64-33f31e17de3a.html

Board/Management Information

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6702H

Indivior PLC

16 November 2018

Indivior PLC - Director Declaration

Indivior PLC confirms that Daniel Tassé, Senior Independent Director, will be appointed Chief Executive Officer of DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq: DBVT), a clinical stage biopharmaceutical company, with effect from November 29, 2018.

There have been no other changes to the information set out in LR 9.6.13R (2) to LR 9.6.13R (6) in respect of Mr Tassé.

This announcement is made in accordance with Listing Rule 9.6.14.

Kathryn Hudson

Company Secretary

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

RDNFKADQPBDDFDD